YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence

Oncotarget

Volumn 6, Issue 10, 2015, Pages 7470-7480

  Sheridan, Christine Moore ^a   Grogan, Tristan R ^b   Nguyen, Hao G ^a   Galet, Colette ^c   Rettig, Matthew B ^c,d   Hsieh, Andrew C ^a,e,f   Ruggero, Davide ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f USA   (United States)

Author keywords

Biomarker; Prostate cancer; PSA recurrence; Translation control; YB 1

Indexed keywords

DNA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN MTA1; TUMOR MARKER; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1; HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; REPRESSOR PROTEIN; YBX1 PROTEIN, HUMAN;

AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; FOLLOW UP; FORECASTING; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTION; PROSTATE CANCER; PROTEIN DATABASE; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MUTATION; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; DISEASE PROGRESSION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; RNA, MESSENGER; Y-BOX-BINDING PROTEIN 1;

EID: 84928412514     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3477     Document Type: Article

References (18)

1. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J and Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. The Journal of urology. 2005; 173(6):1938-1942.
2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA: the journal of the American Medical Association. 1998; 280(11):969-974.
3. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, Fearn PA and Kattan MW. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. Journal of the National Cancer Institute. 2006; 98(10):715-717.
4. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W and Selbach M. Global quantification of mammalian gene expression control. Nature. 2011; 473(7347):337-342.
5. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012.
6. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F and Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 107(32):14134-14139.
7. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer cell. 18(1):11-22.
8. Hsieh AC, Costa M, Zollo O, Davis C, Feldman M, Testa JR, Meyuhas O, Shokat K and Ruggero D. Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBPeIF4E. Cancer cell. 2010; 17(3):249-261.
9. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ and Sorensen PH. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer cell. 2009; 15(5):402-415.
10. Yoo YG, Kong G and Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. The EMBO journal. 2006; 25(6):1231-1241.
11. Nair SS, Li DQ and Kumar R. A core chromatin remodeling factor instructs global chromatin signaling through multivalent reading of nucleosome codes. Mol Cell. 2013; 49(4):704-718.
12. Qian H, Yu J, Li Y, Wang H, Song C, Zhang X, Liang X, Fu M and Lin C. RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model. Biology of the cell/under the auspices of the European Cell Biology Organization. 2007; 99(10):573-581.
13. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature genetics. 2012; 44(6):685-689.
14. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, et al. The mutational landscape of lethal castrationresistant prostate cancer. Nature. 2012; 487(7406):239-243.
15. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X and Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer cell. 2003; 4(3):209-221.
16. Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS and Rubin MA. TMPRSS2:ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia. J Clin Oncol. 2013.
17. Hsieh AC, Truitt ML and Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer. 2011; 105(3):329-336.
18. Benjamin D, Colombi M, Moroni C and Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature reviews Drug discovery. 2011; 10(11):868-880.